A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

NCT07663838 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Randomized
Open-label
Safety
Tolerability
Pharmacokinetics
Bacterial Vaginosis

Interventions

DRUG: GenSci142 capsule
DRUG: clindamycin phosphate vaginal cream

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.